Abiopharma

🔍 Ferguson James J. III (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 102,400 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 102,400.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 135,000 shares of Stock Option at $27.38 per share (Derivative)
  Date: 2026-08-10 | Code: A | Expires: 2036-08-10 | equity_swap_involved: 0 | shares_owned_after: 135,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
• F2: The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.